Carzenide

Carzenide (CAS No.: 138-41-0) is a sulfonamide related small molecule that is broadly categorized as a carbonic anhydrase focused research reagent and synthetic intermediate, and it is described in preclinical literature as a major plasma metabolite of mafenide with utility in mechanistic pharmacology and medicinal chemistry workflows, where its primary biological background is linked to competitive inhibition of carbonic anhydrase II and consequent modulation of bicarbonate carbon dioxide interconversion processes that influence cellular pH homeostasis and ion associated signaling environments relevant to disease model biology; within biomedical research and drug discovery programs, Carzenide is therefore commonly positioned in enzyme inhibition studies, structure activity relationship campaigns, and exploratory phenotypic profiling, including applications in neurologically and oncology relevant experimental systems cited in the literature, while current public summaries do not consistently report standardized quantitative potency metrics for this exact entry and thus activity is most appropriately communicated qualitatively as target engaged inhibitory behavior that should be benchmarked empirically under assay specific conditions, with concentrations or doses used in experiments typically depending on specific experimental designs and research objectives and often spanning standard screening to follow up optimization ranges in cell based and in vivo preclinical models.